Figure 6.
Figure 6. Antitumor effect of TCR-transduced T cells in a self-tolerant setting. RIP-OVAhi mice were challenged with 1 × 105 B16-OVA cells subcutaneously. On day 7, mice received either 1 × 106 OT-I TCR-transduced T cells followed by vaccination with rVV-OVA (left panel in A, black line in B, solid line in C) or vaccination alone (right panel in A, gray line in B, dashed line in C). (A) Blood was sampled and analyzed for the presence of OT-I transduced T cells on day 4 to 14 after adoptive transfer. Each circle represents one mouse; bars, average immune responses. (B) Tumor growth was measured 3 times a week starting at day 7 after inoculation. Dashed lines represent growth curves in individual mice; solid lines, average growth curves; arrow, the start of treatment. (C) Survival curve: Mice were killed when the average tumor diameter exceeded 12.5 mm.

Antitumor effect of TCR-transduced T cells in a self-tolerant setting. RIP-OVAhi mice were challenged with 1 × 105 B16-OVA cells subcutaneously. On day 7, mice received either 1 × 106 OT-I TCR-transduced T cells followed by vaccination with rVV-OVA (left panel in A, black line in B, solid line in C) or vaccination alone (right panel in A, gray line in B, dashed line in C). (A) Blood was sampled and analyzed for the presence of OT-I transduced T cells on day 4 to 14 after adoptive transfer. Each circle represents one mouse; bars, average immune responses. (B) Tumor growth was measured 3 times a week starting at day 7 after inoculation. Dashed lines represent growth curves in individual mice; solid lines, average growth curves; arrow, the start of treatment. (C) Survival curve: Mice were killed when the average tumor diameter exceeded 12.5 mm.

Close Modal

or Create an Account

Close Modal
Close Modal